GenIbet Biopharmaceuticals S.A.

https://www.genibet.com

Global contract development and manufacturing organisation (CDMO), Recipharm, in February 2022 announced the acquisition of GenIbet, a Portuguese CDMO, specialising in the manufacture of biological clinical trial material and novel modalities such as viral vectors, RNA and microbiome. The acquisition forms part of Recipharm’s strategy to grow in the Biologics market, with a particular focus on drug substance manufacturing of novel ATMPs. GenIbet currently works with customer projects in the preclinical and Phase 1 stages and has a track record of developing novel production processes. Through its relationship with not-for-profit research organisation Ibet, the CDMO offers deep scientific expertise and novel solutions where no established production route exists. The deal will provide Recipharm with a platform from which to build its capabilities in new Biologics modalities, leveraging GenIbet’s expertise in viral vectors and vaccines. GenIbet was founded as a spin-off of Ibet - Instituto de Biologia Experimental e Tecnológica - in 2016 and currently has around 70 employees. Its Portuguese facility is located in Lisbon, just 11 km from Recipharm's facility in Lisbon. *

	Start	2016-01-01 established (s-off)
	Group	Recipharm (Group)
	Predecessor	iBET – Instituto de Biologia Experimental e Tecnológica
	Industry	contract manufacturing (biologicals)
	Person	Fortunato, Raquel (GenIbet Biopharmaceuticals 202202 CEO)

	Region	Lisboa (Lisbon)
	Country	Portugal
	Street	Avenida da República Edifício da Unidade Piloto do IBET, Estação Agronómica Nacional
	City	2780-157 Oeiras
	Tel	+ 351-21-446-9484
		Address record changed: 2020-12-02

Basic data	Employees	C: 51 to 100 (2022-02-01)

		* Document for »About Section«: Recipharm AB. (2/1/22). "Press Release: Recipharm Acquires GenIbet to Bolster Biologics Offering".

		Record changed: 2023-11-24